🟢 Gossamer Bio is trading 5.6% up today after filing its first FDA New Drug Application

Gossamer Bio is trading at $11.61, up 5.60% after submitting its first FDA New Drug Application for seralutinib on September 23.

• The application targets pulmonary arterial hypertension and is backed by Phase 3 PROSERA, Phase 2 TORREY, and additional analyses.
• The FDA’s filing decision is expected later in 2026.
• Broader markets remain pressured by elevated Treasury yields and oil prices.